



ISBT128 Standards for Blood and Blood Components: How it Translates to Patient Safety

Diana Teo Blood Services Group Health Sciences Authority Singapore



Declaration of Conflict of Interest


- Member of the ICCBA Board of Directors
- ICCBBA is a non-profit organisation that manages, develops and licenses ISBT 128
- ICCBBA is organised and operated exclusively for charitable, scientific and educational purposes
- ICCBBA Board of Directors are volunteers and do not receive any compensation




The Blood Transfusion Chain



Blood Transfusion Chain



VEIN TO VEIN ORGANISATION











Separation of Blood into Components




6



Production of Modified Components

Cryoprecipitated AHF Fresh Frozen Plasma Fibrinogen Concentrate Liquid Plasma

> Derivative Production



Leucocyte-Reduced Red Cells Irradiated Blood Washed Red Cells Frozen Cellular Components 5% Albumin 20% Albumin Intravenous Immune Globulin Factor VIII Concentrate Factor IX Concentrate

Apheresis Technology



Using apheresis machines, individual blood components can be collected from the donor





Patient Transfusion Safety



9

Haemovigilance

Defined as :

A set of surveillance procedures covering the whole transfusion chain (from the collection of blood and its components to the follow up of its recipients), intended to collect and assess information on unexpected or undesirable events resulting from the therapeutic use of labile blood products, and to prevent their occurrence and recurrence

How Haemovigilance Contributes to Patient Transfusion Safety

- Provides medical community with reliable source of information about untoward effects of blood transfusion
- Indicates corrective measures required to prevent recurrence of some accidents/dysfunctions in transfusion process
- Alerts hospitals and blood services about adverse events that could involve more than a single recipient, including those related to :
 - Transmission of infectious diseases
 - Blood bags, solutions or blood processing

Recipient Haemovigilance

- Adverse transfusion reactions :
 - Immediate reactions during transfusion, e.g.
 haemolysis, febrile non-haemolytic reactions, rash, bacterial contamination, etc
 - Delayed untoward effects after transfusion haemolysis, acute GVHD, etc
 - Occurrence of allo-immunisation against red cell, HLA or platelet antigen
- Identification of transfusion transmitted infections through trace-back and lookback activities


Process Haemovigilance

- Surveillance of errors in the process of both production and transfusion of blood components
 - Systematic surveillance of errors and near misses
 - Monitoring traceability of blood products
 - Surveillance of blood utilisation
- Near miss any error, which if undetected, could result in the determination of wrong blood group, or issue, collection, or administration of an incorrect or unsuitable component but which was recognised before the transfusion took place

Donor Haemovigilance

- Untoward events observed during blood donation
- Data related to donor selection, such as frequency and causes of blood donation exclusion
- Epidemiologic data on the donors found positive in marker screening

Schematic of Haemovigilance



- Homogeneous reporting
- Data analysis

Traceability

- Ability to trace each individual unit of blood or blood components derived thereof from the donor to its final destination, whether this is a patient, a manufacturer of medicinal products or disposal, and vice versa
- Final destination may be:
 - Patient
 - Manufacturing of medicinal products
 - For research and investigational purposes
 - Disposed of
- Essential element is a unique identification numeric or alphanumeric code for each donation, with subsidiary code for each component prepared for that donation linked with data identifying both the donor and recipient

International Movement of Blood, Cell, Tissue Products

- Risk of duplication of identifiers
- Misidentification of products resulting in wrong blood, cells or tissue graft being transfused or implanted
- Weak traceability path
- Need to renumber units when products are received from outside a local area
- Slow or non-existent alert in situations of adverse events requiring product recall

Need for Standardisation

- Bar codes have same meaning globally, thus eliminating language barriers
- Eliminates need to renumber units because identifiers are globally unique
- Improved safety because receiving facility can understand detailed product characteristics
- Reduces software costs
- Facilitates movement into newer technology data transfer mechanisms





19


- Initially developed by working party of the International Society of Blood Transfusion (ISBT)
- First used in blood bank in Estonia in 1997



- Global standard for identification, labelling, and information transfer of human blood, cell, tissue, and organ products
- Provides:
 - Globally unique donation numbering system
 - Internationally standardised product codes
 - Standard data structures for bar coding and electronic data interchange
 - Standardised labelling
- Intended for use across international borders and disparate health care systems
- Managed by ICCBBA

- Specifies:
 - Donation numbering system that ensures globally unique identification
 - Information to be transferred, using internationally agreed reference tables
 - International product reference database
 - Data structures in which this information is placed
 - Bar coding system (linear or 2-dimensional) for transfer of the information on the product label
 - Standard layout for the product label
 - Standard reference for use in electronic messaging

Unique Donation Identification Number (DIN)



Donation Identification Number (DIN)


Process Control Characters

Unique Donation Identification Number (DIN)




Collected by - Blood Services Group HSA, Singapore

Product Codes



Product Codes



FRESH FROZEN PLASMA




PLATELETS









Blood **Product** Label

- **Donation Identification Number** 1 2
 - ABO/Rh Blood Groups
 - Collection Date (optional)
 - **Product Code**


3

4

5

6


- Expiration Date (and Time)
 - Special Testing (optional)



Cell Product Label

- 1 Donation Identification Number
- 2 ABO/RhD
- 3 Product Code
- 4 Expiration Date and Time






Delivery Mechanisms

Comparative size of Code 128 and Data Matrix Symbols

Data Matrix

Code 128






Donation ID number

ABO/Rh

Product Code

Expiration Date/Time

Special Testing results



Radiofrequency Identification

Vox Sanguinis (2009) 97, 50-6

© 2009 The Author(: Journal compilation © 2009 International Society of Blood Transfusio DOI: 10.1111/j.1423-0410.2009.001174.

Tracking blood products in blood centres using radio frequency identification: a comprehensive assessment

Rodeina Davis,¹ Bradley Geiger,² Alfonso Gutierrez,² Julie Heaser² & Dharmaraj Veeramani²

¹BloodCenter of Wisconsin, Milwaukee, WI, USA ²UW RFID Lab, University of Wisconsir

Vox Sanguinis

ORIGINAL PAPER

Radiofrequency identification technology can standardize and document blood collections and transfusions

S. Gerald Sandler, Al Langeberg, Leo DeBandi, Joan Gibble, Charles Wilson, and Charles L. Feldman

Radio frequency identification for prevention of bedside errors

Sunny Dzik

"TO ERR IS HUMAN"

n the landmark publication "To err is human," the Institute of Medicine brought attention to the conse-


BAR CODE OR RADIO FREQUENCY **IDENTIFICATION (RFID) OR BOTH?**

Bar code technology is an established technology within





Using ISBT 128 in the Blood Service



32

Successful Implementation from Codabar to ISBT128 standard in 2006







Why Change ?

- Limitations of ABC Codabar standard
- Old component code system unable to systematically name modified products with multiple attributes, e.g. autologous deglycerolized leuco-reduced RBC irradiated divided unit
- Improved donation look back system with international DIN system
- ISBT 128 global standard for blood services in future

Product Code Mapping – from old to new

Health Science Authority Centre for Transfusion Medicine			T-07 120	ISBT 128	ISBT 128
Maste Product Code	Label Name (ISBT)	ISBT 128 code	ISBT 128 Divided unit 1	Divided unit 2	Divided unit 3
		E0150V00			-
04050 AC1	RED BLOOD CELLS CPD	E0240V00	E0240VA0	E0240VB0	COODU/Da
NEW	RED BLOOD CELLS CPDA-1	E0291V00	E0291VA0	E0291VB0	E0291VBa
AU210 PC3	RED BLOOD CELLS AS1	E0463V00			CODOEVO
NEW	RED BLOOD CELLS AS1 LOW VOL	E0385V0	E0385VAC	E0385VB	0 E0385VB
112.11	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				

Blood Product Labelling







Ability to Incorporate Standard Label for New Blood Products




Blood Collection










Labeling of Blood - Final Confirmation of Suitability for Clinical Use



Issuing Blood for Patient



Thank You